Home > News > Introgen Therapeutics: Empty Promises For Cancer Patients and Shareholders
April 23rd, 2007
Introgen Therapeutics: Empty Promises For Cancer Patients and Shareholders
Abstract:
Because most cancers are amenable to local treatment and because local cancer treatments are administered far more often than systemic cancer treatments, Introgen believes that ADVEXIN therapy can be deposited directly into a patient's cancerous tumor by hypodermic syringe. In those cases for which a systemic therapy may be indicated, the Company is developing the use of a systemically administered nanoparticle formulation system to deliver tumor suppressors.
Source:
biotech.seekingalpha.com
Bookmark:
| Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers/Posters
Metasurfaces smooth light to boost magnetic sensing precision January 30th, 2026
COF scaffold membrane with gate‑lane nanostructure for efficient Li+/Mg2+ separation January 30th, 2026
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||